CA-MAANA
5.12.2018 02:37:04 CET | Business Wire | Press release
Maana, the pioneer of digital knowledge technology, announced the expansion of its international operations with the opening of its London office. Marking the company’s fifth location since its beginnings in 2013, the UK headquarters is located at One Canada Square, an iconic building residing in Canary Wharf – a rich cultural district housing several Fortune Global 500 listed corporations.
This expansion highlights the market’s response to Maana’s solution, the Knowledge Platform, which enables industrial organizations to accelerate decision making across the enterprise, gaining operational efficiencies and resulting in considerable CAPEX and OPEX improvements.
“We are excited to be working with the industry’s top leaders - the catalysts for change - who are breaking the barriers of data and organizational silos so that their enterprises can realize the benefits of a fully digitalized infrastructure,” said Maana Founder and CEO, Babur Ozden. “From our new London office, we will support our growing customer base in Europe and have access to top talent to grow our organization.”
The London operations augment Maana’s existing presence in Palo Alto, California; Bellevue, Washington; Houston, Texas and Dhahran, Saudi Arabia and is home to Maana’s team of experts who have implemented groundbreaking business applications and solutions for companies like IBM, Cisco, Romonet and Elsevier.
“London is a critical hub for the global energy sector and a large segment of our international industrial clients,’ said Kieran O’Byrne, a Principal Customer Solutions Analyst who previously worked for IBM driving the adoption of IBM Watson technologies. “I’m happy to join Maana’s accomplished team of London-based data scientists and customer solutions team members. This marquee location will only further our recruitment activities and will help our customer’s digital transformation journeys.”
About Maana:
Maana is an award-winning digital knowledge platform provider focused on creating CAPEX and OPEX gains for industrial companies. Its unique Computational Knowledge Graph ™ de-silos knowledge from data sources and tacit expertise, to improve decision making across the enterprise. Maana’s investors include Intel Capital, GE Ventures, Chevron Technology Ventures, Saudi Aramco Energy Ventures, Shell Technology Ventures, Accenture Ventures, and China International Capital Corporation.
Maana is privately held with offices in Palo Alto, California; Bellevue, Washington; Houston, Texas, London, UK; and Dhahran, Saudi Arabia. Visit us at https://www.maana.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204006195/en/
Contact:
Linda Madden lmadden@piercom.com (713) 627-2223
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom